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ABSTRACT 
 
KUIKWON KIM. Assessment of Lipopolysaccharide, Isoproterenol and Phenylephrine 
Induced Pathophysiology in Lipoic Acid Synthase Deficient Mice (Under the direction 
of Dr. Nobuyo Maeda.) 
 
--Lipoic acid is a potent antioxidant, and also an essential cofactor for PDH and --
KDH complexes in mitochondria. Investigations have shown complex human diseases are 
associated with oxidative stress. As preventative and therapeutic purposes, studies have 
evaluated effects of lipoic acid on complex human diseases, however, its molecular 
mechanisms and effects remained unknown. 
 In this study, we examined the effects of heterozygous Lias deficiency on LPS 
induced inflammation and adrenergic agonist induced cardiac hypertrophy. We observed 
increased sensitivity of Lias heterozygous mice with elevation of TNF--, decreased and 
delayed recovery of leukocyte and platelet counts accompanied with liver necrosis lung 
inflammation on LPS stimuli. Upon adrenergic agonist stimulation, both genotypes 
developed hypertrophy with increased HW/BW ratio and fibrosis in the heart, however, we 
observed protective effect of Lias deficiency upon stimulation. Our data indicates that Lias 
deficiency results in increased sensitivity upon LPS stimulation, however, protective effect 
against cardiac stimulation. 
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CHAPTER 1 
 
INTRODUCTION 
 
1.1 OXIDATIVE STRESS AND COMPLEX HUMAN DISEASES 
Diabetes, cardiovascular disease, and hypertension are important and complex human 
diseases which are major causes of mortality and morbidity in the world today. Investigations 
have revealed several causative factors of these complex human diseases: genetic factors, 
ethnic background, gender, nutrition, sedentary life styles, and aging (Smith, 2007). A 
concept of oxidative stress and reactive oxygen species has been under extensive debate as a 
contributing factor to the initiation and progression of diabetes, cardiovascular diseases and 
hypertension. Oxidative stress, caused by ROS (reactive oxygen species), is defined as any 
cellular damage resulting from an imbalance between an excessive generation of oxidant 
compounds and insufficient antioxidant defense mechanisms (Sies et al., 1997). 
Oxidative stress may damage cellular macromolecules. For example, oxidative stress 
can biochemically modify proteins and lipids, and often leads to modification and 
fragmentation of amino acid sequences and lipid structures. These modifications result in 
alterations and loss of properties as functional products in the biological system (Cecarini et 
al., 2007; Bartsch et al., 2006). Moreover, oxidative damage, much like ionizing radiation on 
DNA, is known to cause deletion, insertion, inversion and translocation in base pairs, and 
2consequently leads to DNA degradation, single strand breakage and cellular damage (Imlay 
et al., 1998).  
Currently, many clinical and animal models of investigations address issues of the 
reactive oxygen species as one of causative factor, in diabetic complications such as 
atherosclerosis, nephropathy, and polyneuropathy. These studies suggest that antioxidant 
supplements may have preventive and therapeutic effects on these diseases. The outcome of 
these clinical tests are, however, consistently positive. Nevertheless, genetic alterations in the 
genes controlling the body’s antioxidant defense system is another potential candidate that 
may influence the risk for developing these diseases (Wollin et al., 2003; Maritim et al.,
2003; Opara et al., 2002; Gotto, 2003; Ziegler et al., 2004). 
 
1.2 ANTIOXIDANT AND LIPOIC ACID 
According to Halliwell and Gutteridge (1989), an antioxidant is defined as any 
substance that delays or inhibits oxidation of oxidizable substrates, including any molecular 
compounds. Every living organism produces endogenous oxidants as a form of aerobic 
metabolism and endogenous buffering systems naturally balance oxidants and free radicals 
by initiating antioxidant defense mechanisms. Sies et al. summarizes and describes three 
principle functions of antioxidant defense mechanisms - prevention, interception, and repair 
(Sies et al., 1997).  
Prevention of endogenous oxidative stress from oxidative metabolism can be 
achieved by several enzymatic activities. Removing or transferring radicals and enzymes 
including glutathione S-transferases, plays a role of prevention. Strategies of interception of 
free radicals and oxidative stress also play an important role in transferring damaging 
3radicals away from sensitive cells and tissues. Several enzymatic reactions and non-
enzymatic molecular compounds are responsible for intercepting harmful free radicals 
including-vitamin E, carotenoids, superoxide dismutase, catalases and glutathoione 
peroxidases. Elevated rates of harmful radicals and accumulation of oxidants under certain 
physiological conditions may damage structures of DNA, proteins and lipids. However, these 
molecular and cellular damages can be repaired by specific repair mechanisms or substituted 
by multiple lipolytic and proteolytic enzyme complexes (Sies et al., 1997).  
In the last decade, alpha-lipoic acid (LA or 6, 8-thioctic acid) gained much attention 
as a potent and powerful antioxidant compound because of its preventive and therapeutic 
effects on many types of complex human diseases, including diabetes, atherosclerosis, and 
neurodegenerative diseases (Packer et al., 2001; Bilska and Wlodek, 2005; Bielarczyk et al.,
2006; Ziegler et al., 2004), (Figure 1.1.). 
Lipoic acid (LA) is a naturally occurring compound and a crucial disulfide/dithiol 
cofactor for pyruvate dehydrogenase (PDH), and alpha-ketogluterate dehydrogenase (--
KDH), which are important multienzyme complexes in energy metabolism in mitochondria 
(Reed et al., 1951), (Figure 1.2.). As one of the most potent antioxidants, LA and its reduced 
form DHLA, have drawn much interest because of its several unique features (Packer et al.,
2001; Moini et al., 2002). First, LA/DHLA is an amphiphilic compound and easily crosses 
the blood brain barrier. Second, it can quench free radicals and chelate heavy metals. Third, it 
interacts with other antioxidants such as vitamin C, vitamin E, glutathione coenzyme Q10, 
and ubiquinone, and metabolically can be regenerated by other antioxidants (Gotz et al.,
1994; Han et al., 1997; Kozlov et al., 1999; Packer et al., 1995; Scholich et al., 1989). 
4Figure 1.1. Molecular structures of lipoic acid. Lipoic acid is synthesized from octanoic 
acid and an unknown sulfur source in cell by lipoic acid synthase. Lipoic acid exists in two 
forms, oxidizied and reduced which both act as strong antioxidants. Naturally, lipoic acid is 
formed as lipoamide complex (lysine side chain). (Bilska and Wlodek, 2001; Packer et al.,
2001, 2002; Moini et al., 2002). 
 
5Krebs cycle
 
Figure 1.2. Oxidative metabolism in mitochondria and lipoic acid. Pyruvate is transported 
into mitochondria and acetyl-CoA is synthesized by pyruvate dehydrogenase complex. TCA 
cycle begins with transferring two carbons, acetyl CoA, to four carbon acceptor, oxaloacetate 
to form six carbon citrate. This Citrate goes through a series of cycles of reducing its carbon 
number and producing NADH, FADH2, CO2 and GTP. Lipoic acid is a crucial cofactor for 
pyruvate dehydrogenase and alpha-ketogluterate dehydrogenase (Created based on the 
Marcotte, Fall, 2005 Chapter 16, Citric Acid Cycle)  
 
61.3 LIPOIC ACID SYNTHASE AND MOUSE MODEL OF DEFICIENCY 
Lipoic acid is universally present in prokaryotes and eukaryotes, and its endogenous 
production is regulated by lipoic acid synthase (Lias) from octanoic acid and an unknown 
sulfur source (Packer et al., 2001; Jordan et al., 1997; Miller et al., 2000). The lipoic acid 
synthase gene is shared by many species (Morikawa et al., 2001), and is encoded by the 
nuclear gene Lias located on mouse chromosome 5.
Since it has been shown that LA plays crucial roles as a potent antioxidant in several 
biological systems, and as a critical cofactor of multi enzyme complexes that are important in 
energy metabolism, Lias is a potential candidate gene for cardiovascular and metabolic 
diseases. To test this hypothesis, our laboratory generated mice deficient in lipoic acid 
synthase. We did this in order to explore the genetic and physiological effects of lipoic acid 
synthase deficiency and to assess whether the endogenous deficiency is associated with 
increased susceptibility to diabetes and cardiovascular diseases. Homozygous Lias deficient 
mice die in utero, whereas heterozygous deficient mice survive with a decreased antioxidant 
capacity compared to wild type littermates (Yi et al., 2005). These results indicate that lipoic 
acid synthase is an essential enzyme in normal embryonic development, and synthesis of 
endogenous LA is also crucial due to its roles as cofactor and antioxidant. 
In this study, I have investigated physiological effects of Lias heterozygous 
deficiency and assessed whether the reduction of endogenous lipoic acid production is 
associated with the initiation and progression of various forms of human disease under 
certain pathological conditions. To this end, I administered LPS (lipopolysaccharide), ISO 
(isoproterenol) and PE (phenylephrine) to Lias heterozygous deficient mice and characterized 
7genetic effects of Lias heterozygous deficiency upon exogenous oxidative stimulation such 
as lipopolysaccharide, isoproterenol and phenylephrine.. 
 
CHAPTER 2 
 
ASSESSMENT OF LIPOPOLYSACCHARIDE INDUCED PATHOPHYSIOLOGY IN 
LIPOIC ACID SYNTHASE DEFICIENT MICE 
 
2.1 INTRODUCTION 
Oxidative stress or reactive oxygen species (ROS) is defined as cellular damages 
resulting from an imbalance between an excessive generation of oxidant compounds and 
insufficient antioxidant defense mechanism (Sies et al., 1997). Reactive oxygen species have 
been extensively studied and evidences indicated that oxidative stress and oxidation process 
may damage cellular macromolecules and resulting in progression of several chronic diseases 
(Wollin et al., 2003). Currently, it has been observed that complex human diseases such as 
atherosclerosis and diabetes are associated with increased levels of cellular oxidative stress 
(Madamanchi et al., 2005; Sachidanandam et al., 2005, Maritim et al., 2003). Up to date, 
several experimental models and clinical investigations have evaluated benefits of LA/DHLA 
as a potent antioxidant in prevention and treatment of diabetes and cardiovascular diseases 
(Wollin et al., 2003; Osiecki et al., 2004). However, its molecular anti-oxidizing mechanism 
involved in reduction of naturally occurred oxidative stress and pathophysiological roles 
associated with complex human diseases have not been clarified in details. Moreover, there is 
no concrete knowledge describing how the endogenous lipoic acid synthesis is modified 
under certain pathological conditions and whether the genetic alterations of lipoic acid 
synthesis will modify the development of diseases (Yi et al., 2005).  
9To identify underlying mechanisms of lipoic acid as an antioxidant and unravel 
pathophysiological roles of lipoic acid against complex human diseases, we used lipoic acid 
synthase deficient mice generated by targeting Lias gene responsible for synthesis and 
endogenous production of lipoic acid (Yi et al., 2005). Previous experimental results showed 
that homozygous Lias deficient mice die in utero whereas heterozygous survive with 
increased oxidative stress, reduced antioxidant capacity compared to wild type littermates. 
These findings suggest that lipoic acid and its synthesis play crucial roles in normal 
development, energy metabolism and endogenous antioxidizing mechanism (Yi et al., 2005), 
and It can be speculated that Lias deficiency may be more vulnerable to various forms of 
complex human diseases associated with exogenous oxidative stress. 
LPS (lipopolysaccharides) is a large molecular compound composed of lipid and 
carbohydrate, and is a major protective cellular structure of Gram-negative bacteria 
(Henderson et al., 1996). Commonly, LPS acts as an endotoxin that induces septic shock and 
cascade of systemic pro-inflammatory reactions triggered by macrophages, cardiovascular 
failures, internal organ damage and even death (Henderson et al., 1996; Lynn et al., 1998). In 
addition, LPS also can increase reactive oxygen species production by generating free 
radicals which lead to oxidative stress at given species, thus it is a widely accepted and used 
reagent to induce oxidative stress (Galley et al., 1997; Goode et al., 1995; Loft et al., 1998). 
In this study, we tested hypothesis that reduced lipoic acid synthase gene expression 
increases lipopolysaccharide-induced oxidative stress and tissue damage in lipoic acid 
synthase heterozygous deficient mice compared to wild type mice. Our data demonstrate that 
lipoic acid synthase heterozygous deficient mice show an increased recruitment of 
inflammatory cells to lung and liver and markedly enhanced tissue damage following an LPS 
10
administration, and implicates that Lias deficiency has increased sensitivity upon LPS-
induced inflammatory reaction and septic response. 
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Gram negative Bacteria
Bacterial Endotoxin
(LPS)
Macrophage Recruitment
Inflammatory Response
Cytokines Chemokines Free Radicals
Septic Response
Figure 2.1. The LPS and pathway of sepsis. LPS is produced by the Gram negative 
bacteria. Upon administration, recruited macrophages generate various cytokines, 
chemokines and free radicals which induce local inflammation. Prolonged inflammation will 
result in septic shock and organ damage. 
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2.2 MATERIALS AND METHODS 
2.2.1 Mice and LPS administration 
The Lias heterozygous mice and their wild type litter mates were F1 between wild 
type C57BL/6J mice and 129/SvEv mice heterozygous for the disrupted Lias gene. 
Experiments were conducted on young (3 months old) female Lias heterozygous and wild 
type mice. Lipopolysaccharide (Sigma, E. Coli 055:B5) of 20 mg/kg of body weight was 
administered intraperitoneally (I.P.) to conscious mice whereas control mice received PBS. 
All animals were housed at the room temperature (22-24°C) with free access to laboratory 
chow and drinking water and were exposed to alternate cycles of 12-hour light and dark 
cycle until the time of sacrifice. Mice were maintained according to the Guide for Care and 
Use of Laboratory Animals, published by the NIH in U.S., and all experiments were carried 
out in accordance with protocols approved by the IACUC of the University of North Carolina 
at Chapel Hill. 
 
2.2.2 Plasma Metabolites, Body Temperature 
Mice were fasted for approximately 4-5 hours before collection. Retro-orbital 
bleeding was performed with heparinized capillaries to obtain blood from each animal. 
Collection tubes were anti-coagulated with 0.5M of EDTA and whole blood was then 
centrifuged at 4°C to separate the plasma. Plasma levels of glucose (WAKO, Richmond, 
VA), triglyceride (Stanbio, Boernl, TX), and cholesterol (WAKO, Richmond, VA) were 
determined by enzymatic reaction of 2ul of plasma in 200ul of commercially available 
solution followed by spectrophotometer quantitation. Rectal temperature sensors (Physitemp, 
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Physitemp Instruments Inc, Co., Clifton, NJ) was placed and body temperature of each 
animal was recorded before and every 60 minutes for 4 hour after LPS administration. 
 
2.2.3 Hematological and Blood Assays 
Retro-orbitally drawn blood at 0hr, 2hr, 4hr, 8hr and 16hr after LPS injection was 
analyzed for hematological assays. Leukocyte and platelet counts were measured on an 
Animal Blood Counter, CBC-Diff™ (Heska Inc. Loveland, CD). LPS-induced liver and 
kidney damages were assessed by measuring the activities of plasma alanine 
aminotransferase (ALT), aspartate aminotransferase (AST) and blood urea nitrogen (BUN) 
using a Vitro 250 Chemical Analyzer (Ortho-Clinical Diagnostics, Inc., Raritan, NJ). Plasma 
levels of cytokines and chemokines were quantified by commercially available kit which is 
specific for mouse (Linco Research, St. Charles, MI). Levels of IL-6, IL-10 (Interleukin-10), 
TNF-- (Tumor necrosis factor-alpha) and MCP-1 (Monocyte chemoattractant protein-1) 
were measured on the Luminex 100 system and analyzed with the Masterplex QT 1.2 or 
LMAT software (Luminex Corporation, Austin, TX). 
 
2.2.4 Biochemical Analyses and Tissue Preparation 
Liver, lung, heart, kidney, spleen and pancreas were surgically removed and quick 
frozen in liquid nitrogen and stored at -80°C for subsequent biochemical analyses. Tissues 
were homogenized in 1ml of ice-cold 50mM potassium phosphate buffer (pH 7.4) and then 
centrifuged at 4°C of 10,000g for 30 minutes. The supernatants were used for measurement 
of NOx, GSH and TBARS. The infiltration and activation of neutrophils were determined 
indirectly by measuring the activity of MPO (myeloperoxidase) in lung and hepatic 
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homogenates as described (Suzuki et al., 1994). Measurement of the antioxidant capacity, 
GSH (reduced glutathione) level of the erythrocyte and tissue was determined using a 
commercially available kit (Calbiochem, San Diego, CA) following the manufactures’ 
protocol. Measurement of the lipid peroxidation, TBARS (Thiobarbituric Acid Reactive 
Substances) assay and NO (Nitric Oxide, Nitrate/Nitrite Oxide concentration) was measured. 
TBARS assay was performed in the supernatant of homogenized tissue lysate of heart, liver 
and kidney as previously described (Lapenna et al., 2001) using MDA (malondialdehyde) as 
a standard. For NO assay, plasma levels of Nitrate/Nitrite Oxide concentration was 
determined at 0hr, 4hr and 8hr after LPS administration by using commercially available kit 
(Cayman, Ann Arbor, MI) following the manufactures’ protocol, and the concentration of 
nitrite was calculated from a standard curve of NaNO2 (5-35 mmol/L) and expressed as 
mmol/L of nitrate. Nuclear extract of livers was freshly prepared by using the Nuclear 
Extraction Kit (Active Motif, Carlsbad, CA) following manufactures’ protocol. NF-GH 
activation in liver tissues was monitored using a TransAM NF-GH p65 Transcription Factor 
Assay Kit (Active Motif, Carlsbad, CA) following manufactures’ protocol. Protein 
concentrations of tissue homogenates were determined based on the Bradford method (Bio-
Rad Laboratories, Hercules, CA) and known concentrations of BSA (bovine serum albumin) 
was used as a standard. 
 
2.2.5 RNA Isolation & Gene Expression Analysis 
Tissue from liver, heart, spleen, kidney and pancreas were transferred immediately 
after surgical removal and stored in RNA later solution (Ambion, Austin, TX) overnight. 
RNA isolation was done by the ABI 6700 RNA automated robot, approximately 30 to 100mg 
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of tissue was weighed and was put into 1ml of lysis buffer (ABI, diluted with 1X PBS). 
Samples were then homogenized thoroughly for 30 seconds for two times. Cooled down for 
five minutes and stored overnight at 4°C. Roughly, 10 to 20Pl of proteinase K (10ug/Pl) was 
added into lysate, incubated at room temperature for an hour and then cooled down at ice for 
five minutes. Approximately, 200Pl out of 1ml of lysate was applied to ABI 6700 RNA 
extraction robot. Remaining steps were followed by the manufactures’ protocol. Levels and 
patterns of mRNA expression of Lias, MnSOD, TNF-, ICAM, VCAM, E-Selectin, L-
Selectin, GRO, MIP1-, MCP1, eNOS, iNOS, IFN-!, NF-"# were determined by TaqMan 
real-time quantitative reverse transcription PCR (RT-PCR), with H-actin as the reference 
gene in each reaction (Kim et al., 2002). Sequences of all TaqMan primers and probes are 
summarized in Table 2.1. 
 
2.2.6 Histological Analysis and Immunofluorescence 
Liver, heart, kidney, spleen and pancreas tissue samples were surgically removed 
and immediately kept in 4% PFA (pH 7.4) solution, and then fixed overnight. Samples were 
trimmed and sent to the Histological Core Facility at University of North Carolina at Chapel 
Hill for further process. Five micron sections were stained with H&E (hematoxylin and 
eosin) and Mason’s trichrome staining. Lipoic acid in tissue sections were visualized by the 
immunoflourescence procedures with a rabbit anti-lipoic acid polyclonal antibody 
(Calbiochem, San Diego, CA) and a goat anti-rabbit IgG antibody conjugated with Alexa 
Fluor 594 (Invitrogen, Carlsbad, CA). Slides were examined using a Nikon Eclipse TE300 
microscope attached with either a Nikon D100 camera or a CoolSnap Photometrics HQ 
camera from Media Cybernetics with Image-Pro Plus 5.0 software. 
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2.2.7 Statistical Analysis 
Statistical analyses were carried out with JMP software (SAS, Cary, NC). Values 
reported here is mean ± SEM. Effect of genotype and drug treatment was analyzed by two-
factorial ANOVA followed by Tukey-Kramer test. Student’s t test was used for comparison 
between heterozygous and wild type mice group. P<0.05 was considered as a statistical 
significance. 
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2.3 RESULTS 
 
2.3.1 Energy Metabolism in Lias Heterozygous deficient mice after LPS administration 
Since lipoic acid is an important cofactor for the enzyme complexes locating in the 
TCA cycle and participating in oxidative metabolism of glucose, blood glucose and body 
temperature at different time points following LPS administration were monitored in the Lias 
heterozygous mice (n=10) and wild type mice (n=12). Similar as septic shock patients, the 
LPS-administered mice showed a typical biphasic response of hepatic carbohydrate 
metabolism (Maitra et al., 1999) with an initial hyperglycemia followed by a profound 
hypoglycemic phase (Fig 2.2.). No significant difference was observed in blood glucose 
levels at any time point between Lias heterozygous and wild type mice, however, the blood 
glucose levels in the Lias heterozygous mice tended to be higher at basal level and during 
hyperglycemic phase but lower during the hypoglycemic phase resulting in a steeper drop 
between 1 hour to 2 hour after treatment of LPS than wild type mice group (P<0.0012). 
Marked change in body temperature, either fever or hypothermia, is a hallmark of 
endotoxemia in laboratory animal experiments (Kozak et al., 1994), and this was observed in 
all LPS-administered mice in our study with the body temperature reduction to mean of 28°C 
(Fig 2.3.). These data suggest that decreased energy metabolism in the wild type mice upon 
LPS treatment is the same in the mice with reduced Lias gene activity. 
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Figure 2.2. Measurement of blood glucose level before and after LPS administration. 
Blood glucose level was measured before and after the LPS administration in Lias 
heterozygous and wild type groups. Biphasic response (Hyperglycemia and hypoglycemia) 
was observed after LPS administration in both genotypes; However, both genotypes 
developed hypoglycemia. 
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Figure 2.3. The measurement of body temperature before and after LPS 
administration. The body temperature was measured before and after LPS administration in 
both genotypes. Both genotypes showed decreased body temperature (hypothermia) after 
LPS administration, however, genotypic difference was not observed. 
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2.3.2 Peripheral WBC and Platelet counts in Lias heterozygous deficient mice after LPS 
administration 
The platelet counts fell following injection of LPS similarly in mice of both 
genotypes until at 4 hour when response of the two genotypes diverged. At 8 hour time point, 
platelet counts in Lias heterozygous mice continued to reduce whereas wild type group 
started to recover, however, the counts of the platelet of these two groups reached to similar 
levels at 16 hour time point (Fig 2.4.). Mean platelet volume in these two groups did not 
change during this course (Fig 2.5.) implying that decreased platelet numbers in Lias 
heterozygous mice was not due to the reduction of platelet generation in bone marrow. 
Likewise, circulating WBC was markedly decreased, reaching to a minimum (Approximately 
20%) at 4 hour post-injection of LPS and followed by a return back to an about 50% normal 
level at 8 hour in wild type mice group. In contrast, Lias heterozygous mice showed a similar 
degree of reduction but a significant delay in the recovery at 8 hour and 16 hour compared to 
wild type mice (Fig 2.6.).  
To test whether the decreased levels of WBC and platelets were due to enhanced 
sequestration in tissues in lungs and liver upon LPS challenged Lias heterozygous animals, 
we measured the activity of MPO, an enzyme primarily produced by neutrophils in lung and 
liver at 8 hour after LPS challenge. As shown in Fig 2.7., MPO activities in the Lias 
heterozygous mice were twice as much as that of wild type tissues (Lung:1.13±0.18 U/mg 
protein vs 0.49±0.06 U/mg protein, P<0.05; Liver:0.565±0.1 U/mg protein vs 0.232±0.059 
U/mg protein P<0.05). These data suggest that lungs and livers of Lias heterozygous mice 
contain more WBC at 8 hour and 16 hour and that the release of marginated leukocytes to 
circulation is significantly impaired in Lias heterozygous mice compared to wild type mice. 
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Figure 2.4. Measurement of platelet counts before and after LPS administration. 
Platelet counts were measured before and after LPS administration. Four hours after LPS 
administration, Lias heterozygous mice show low counts of platelet and delayed recovery of 
platelet compared to wild type mice. Both reached similar platelet counts after 16 hours. 
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Figure 2.5. Measurement of mean platelet volume before and after LPS administration. 
Mean platelet volume was measured before and after LPS administration. Their average 
platelet volume did not change before and after LPS administration, and genotypic difference 
was not observed. 
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Figure 2.6. Measurement of white blood cell counts before and after LPS 
administration. WBC counts before and after LPS administration was measured. Both 
showed decreased WBC after LPS administration, however, Lias heterozygous mice showed 
significant reduction in WBC counts and delayed recovery compared to wild type littermates. 
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Figure 2.7. Measurement of MPO activity in lung and liver. The levels of MPO 
(myeloperoxidase) in llung and liver after LPS administration. The MPO activity of the Lias 
heterozygous mice in lung and liver significantly increased upon LPS administration due to 
increased levels of neutrophil activity. 
 
25
2.3.3 Organ damage in Lias heterozygous deficient mice after LPS administration 
Leukocytes sequestration in the tissues is thought to be responsible for the organ 
damage induced by LPS (Lukaszewicz et al.,1996). Serum levels of ALT, AST and BUN in 
the Lias heterozygous and wild type mice were not different in the basal. However, mean 
serum levels of AST was much higher in the Lias heterozygous mice group than the wild 
type mice (Lias +/-: 412 U/L, Lias +/+: 178 U/L, P<0.001, Fig 2.8.), and the ALT level was 
also significantly elevated in the Lias heterozygous mice compared to wild type mice group 
(Lias +/-: 100 U/L, Lias +/+: 68 U/L, P<0.01, Fig 2.9.). These data suggest that Lias 
heterozygous mice are much more sensitive to LPS-induced hepatic damage. Similarly, 
serum BUN levels in Lias heterozygous mice and wild type were the same before LPS 
challenge (Lias +/-: 10.4±1.3 mg/dl, Lias +/+: 11.5±1.7mg/dl), but marked increase was 
detected in both Lias heterozygous and wild type mice after LPS challenge (Lias +/-: 
41.6±5.7mg/dl, Lias +/+: 36.4±2.3mg/dl, P=0.25, Fig 2.10.). The genotypic effect on serum 
BUN levels was not significant suggesting that the reduced Lias had a lesser effect on the 
kidney damage than on the liver damage at the 8 hour time point.  
Light microscopic evaluation of the lung and liver in both genotypes at 8 hour after 
LPS challenge confirmed that the infiltration of inflammatory cells are more extent in the 
Lias heterozygous mice group than in the wild type mice (Fig 2.11.). Neutrophil infiltration 
in the lung of the Lias heterozygous mice was also more evident compared to that of wild 
type mice group. One Lias heterozygous mouse out of total 17 mice had severe liver necrosis 
while one wild type mouse out of total 16 mice had small but histologically detectable lover 
necrosis. These observations indicate that the delayed recovery of platelets and leukocyte 
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counts in circulation of Lias heterozygous mice is associated with enhanced tissue damage in 
response to LPS challenge.  
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Figure 2.8. Measurements of plasma AST (aspartate aminotransferase) before and after 
LPS administration. Plasma levels of AST (an indicator of liver damage) were measured 
before and after LPS administration. Before LPS administration, both genotypes showed no 
sign of liver damage, however, AST level significantly increased in the Lias heterozygous 
mice compared to wild type after eight hours of LPS administration. (Black bar represents 
Lias heterozygous mice and solid bar represents wild type mice, number represents the 
number of animal used for experiment). 
.
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Figure 2.9. Measurement of plasma ALT (alanine aminotransferase) before and after 
LPS administration. Plasma levels of ALT (an indicator of liver damage) were measured 
before and after LPS administration. Before LPS administration, both genotypes showed no 
sign of liver damage, however, ALT level significantly increased in the Lias heterozygous 
mice compared to wild type after eight hours of LPS administration. (Black bar represents 
Lias heterozygous mice and solid bar represents wild type mice, number represents the 
number of animal used for experiment). 
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Figure 2.10. Measurement of plasma BUN (Blood urea nitrogen) before and after LPS 
administration. Plasma levels of BUN (indicator of kidney damage) were measured before 
and after LPS administration. Before LPS administration, both genotypes showed no sign of 
kidney damage, however, the levels of BUN significantly increased in both groups but no 
genotypic difference was observed after LPS administration. 
 
30
A
B
C
D
Lias+/-
Lias+/+
 
Figure 2.11. Histological analysis of lung and liver after LPS administration. H&E 
staining of lung and liver tissue. After LPS administration, Lias heterozygous mice showed 
enhanced infiltration of inflammatory cells and tissue damage in liver and lung compared to 
wild type littermates. 
A, B, lung sections of both genotypes after LPS administration; C, D, liver sections of both 
genotypes after LPS administration 
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2.3.4 Induction of Plasma Cytokines 
To examine whether the increased tissue damage is related to enhanced 
inflammatory response to LPS challenge in the Lias heterozygous mice, serum levels of the 
pro-inflammatory cytokines, TNF--, IL-6, MCP-1 and the anti-inflammatory cytokine IL-10 
were measured at 0, 2, 4, and 8 hour after LPS injection. Basal level of TNF--, IL-6, IL-10 
and MCP-1 in sera of Lias heterozygous mice and wild type mice group was not different. At 
2 hour after LPS administration, plasma cytokine levels were significantly increased 
compared to basal level. The mean serum TNF-- level at 2 hour in Lias heterozygous mice 
was significantly higher than in wild type mice (Lias +/-: 7.4±0.5 ng/ml, Lias +/+: 
4.3±1.0ng/ml, P<0.01 Fig 2.12.). IL-10 was also higher in the Lias heterozygous mice at 2 
hour, but the difference was not statistically different (Fig 2.13.). Both TNF-- and IL-10 
levels were decreased with the time and at 8 hour time point, but the serum levels in both 
genotypes were not different. In contrast, IL-6 and MCP-1 levels were increased at 2 hours 
after LPS injection and remained relatively high at 8 hours in mice with both genotypes (Fig 
2.14., Fig 2.15.). These data indicate that the inflammatory cytokine response in the mice 
with heterozygous deficiency of the Lias may be exaggerated in the very early phase of 
infection, but not in the later phase of infection.  
NF-GH regulates inflammatory reactions through its binding to the promoter regions 
of many genes including TNF--. To investigate whether the sensitivity of Lias heterozygous 
mice to LPS challenge occurs via the activation of NF-GH signaling pathway, NF-GH DNA-
binding activity was examined in the nuclear extracts of liver tissue from the untreated and 
LPS-administered mice. NF-GH p65 was highly activated in the livers of mice of the both 
genotypes at 8 hour after LPS challenge as demonstrated by the five fold increase in the 
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absorption, at the OD450nm (0.49±0.1 vs 0.1±0.01, P<0.001, Fig 2.16.). However, levels of 
NF-GH activation in Lias heterozygous and wild type mice were virtually were identical, 
suggesting that the activation of NF-GH is not responsible for the increased tissue damage 
seen in the Lias heterozygous mice group at 8 hour post infection. 
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Figure 2.12. Measurement of plasma TNF-alpha before and after LPS administration. 
The plasma levels of TNF-alpha significantly increased after 2 hour of LPS administration in 
Lias heterozygous mice compared to wild type littermates, however, both genotypes reached 
similar levels after 4 hour of LPS administration. 
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Figure 2.13. Measurement of IL-10 before and after LPS administration. The plasma 
levels of IL-10 increased after 2 hour of LPS administration in Lias heterozygous mice 
compared to wild type littermates but did not reach statistical significance. However, both 
genotypes reached similar levels after 4 hour of LPS administration. 
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Figure 2.14. Measurement of plasma IL-6 before and after LPS administration. The 
plasma levels of IL-6 increased after 2 hour of LPS administration in groups of mice, 
however no genotypic difference was observed. 
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Figure 2.15. Measurement of plasma MCP1 before and after LPS administration. After 
LPS administration, plasma levels of MCP1 increased in both genotypes and remained 
relatively high during the experiment. No genotypic difference was observed. 
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Figure 2.16. Measurement of NF-BC in liver before and after LPS administration. After 
LPS administration, NF-VH activation was significantly increased in both genotypes. 
However, genotypic difference was not observed in NF-VH activity upon LPS administration. 
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2.3.5 Increased Oxidative Stress in Lung and Liver 
LPS-induced septic shock increases oxidative stress (Galley et al., 1997; Goode et 
al., 1995; Hewett et al., 1993; Macdonald et al., 2003; Shenkar et al., 1999; Sakaguchi et al.,
2006; Takeda et al., 1986). We, therefore, examined GSH in erythrocyte, lung and liver, and 
TBARS in plasma, lung and liver at 8 hour after LPS-injection. Plasma TBARS was 
increased and erythrocyte GSH was decreased by LPS challenge, but there was no 
statistically significant difference between two genotypes. In contrast, TBARS in lungs and 
livers of Lias heterozygous mice at 8 hour post infection were 70% and 100% more 
respectively, than those in the wild type mice group while liver GSH was significantly lower 
(Fig 2.17., Fig 2.18.). Similarly, serum nitrite levels were increased 10 times in response to 
LPS challenge in the both wild type (211.2±20.9PM at 8 hour vs. 20±2.1PM basal level, 
P<0.001), but not statistically significant (Fig 2.19.). The Lias heterozygous mice had 
slightly higher NOx levels in the liver than wild type mice (Lias +/-: 0.91±0.19Pmol/mg 
protein, Lias +/+:0.81±0.10Pmol/mg protein, P=0.6), but the difference between two 
genotypes was not significant. 
As expected, the basal expression of the Lias gene assessed by the real time RT-PCR 
in the livers of the Lias heterozygous mice were approximately 50% of that in the wild type 
mice. At 8 hour after LPS-injection, the Lias gene expression was markedly reduced by in 
both groups by 70% (P<0.001, Fig 2.20.). Immunostaining of the liver sections with anti-LA 
antibody showed that the number of LA-positive hepatocytes of the Lias heterozygous mice 
was much less than wild type mice group after LPS-challenge (Fig 2.21) suggesting that, in 
addition to the reduced lipoic acid production, lipoic acid in the liver of Lias heterozygous 
mice was consumed to a greater extent. These results suggest that although the general 
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oxidative stress in response to LPS treatment as measured in the plasma is the same, the 
tissue of the Lias heterozygous mice demonstrate increased oxidative stress than those of 
wild type mice, reflecting an impaired endogenous antioxidant reserve and/or increased 
damage in these tissues. 
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Figure 2.17. Measurement of TBARS in lung and liver after LPS administration. After 
LPS administration, levels of lipid peroxidation, TBARS, significantly increased in lung and 
liver of Lias heterozygous mice compared to wild type littermates. (Black bar represents Lias 
heterozygous mice and solid bar represents wild type mice, number represents the number of 
animal used for experiment). 
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Figure 2.18. Measurement of GSH in lung and liver after LPS administration. After LPS 
administration, levels of antioxidant capacity, GSH (reduced glutathione), significantly 
decreased in liver and lung of Lias heterozygous mice compared to wild type littermates. 
(Black bar represents Lias heterozygous mice and solid bar represents wild type mice, 
number represents the number of animal used for experiment). 
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Figure 2.19. Measurement of plasma NO before and after LPS administration. Before 
LPS administration, plasma levels of NO (indicator of oxidative stress) shows relatively low, 
however, both genotypes significantly increased after LPS administration. No genotypic 
difference was observed upon LPS administration. 
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Figure 2.20. Measurement of lias gene activity in liver before and after LPS 
administration. As expected, Lias heterozygous mice showed half reduced levels of Lias 
gene in the liver. After LPS administration, lias gene expression was significantly decreased 
in both genotypes, however, genotypic difference was not observed. 
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Figure 2.21. Immunoflourescence of lipoic acid in liver after LPS administration. The 
level of lipoic acid upon LPS administration is decreased more in Lias heterozygous mice 
compared to wild type littermates, and this indicates that lipoic acid is consumed more in 
Lias heterozygous mice compared to wild type mice.  
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2.3.6 Enhanced Expression of Inflammatory Genes 
To gain further insights into the mechanisms underlying the enhanced tissue 
sequestration of leukocytes in the Lias heterozygous mice compared to wild type mice, we 
analyzed the expression of some of the LPS-inducible genes in the livers at 8 hour post 
infection by real time RT-PCR (Table 2.2.). Among cytokines and chemokines important for 
recruiting white blood cells into the tissues, expression in the Lias heterozygous livers of 
GRO gene, a major chemoattractant protein for neutrophils, was three fold that in the wild 
type liver, while those for MIP1- and MCP1, two major chemoattractant proteins for 
macrophages, were not significantly different between two groups. The expression trend of 
TNF- was higher in Lias heterozygous mice than wild type mice. Of the genes related to 
leukocyte trafficking, small increases were seen in intracellular cell adhesion molecule 
(ICAM-1) and vascular cell adhesion molecule (VCAM-1) expression in the Lias 
heterozygous mice livers, but expressions of L-selectin and E-selectin were not different. 
Lias genotype had no effects on the expression of the genes for MnSOD, iNOS and CD14 in 
the liver. Taken together, these gene expression data suggest that the impaired recovery of 
the plasma WBC and platelet counts after LPS-administration in the Lias heterozygous mice 
is likely due to enhanced tissue response leading to continual recruitments of neutrophils via 
GRO and infiltration through increased expression of cell adhesion molecules on 
endothelium.  
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Table 2.1. 
TaqMan Primers and Probes 
Gene  Type   Sequence (5’-3’) 
Lias  Forward GGG TCT GGA TTA TGT TGT CC 
 Reverse CAT GAC ACG GTC TTG GCG AT 
 Probe  f CCC GTC GGC CAC ATC ATC TCG AT q 
 
MnSOD Forward AAG GAG CAA GGT CGC TTA CA 
 Reverse AGC AGC GGA ATA AGG CCT GT 
 Probe  f TGC TGC CTG CTC TAA TCA GGA CCC A q 
 
TNF-a  Forward CAC ACT CAG ATC ATC TTC TCA A 
 Reverse AGC TGC TCC TCC ACT TGG T 
 Probe  f AGC CTG TAG CCC ACG TCG TAG CA q 
 
ICAM-1 Forward ACT GAG GAG TTC GAC AGA AC 
 Reverse AGG ACC GGA GCT GAA AAG TT 
 Probe  f CCG CTA GCT CCA AAA CGC AGC G q 
 
VCAM-1 Forward GTA TCC ACG TGG ACA TCT AC 
 Reverse CAC TTG ACT GTG ACC GGC TT 
 Probe  f TCA ATT CAG TGG CCC CCT GGA GG q 
 
E-Selectin Forward GGA TGC CGC CTA CCT GTG AA 
 Reverse AGG TTC CTG CCG CAG AAA GT 
 Probe  f TCA GCC CCA CCC GTC CCT TGG TA q 
 
L-Selectin Forward AAC ACA GTG TGG AGC ATC TG 
 Reverse CTC CAA AGG CTC ACA CTG GA 
 Probe  f TGG TCA TCT CCA GAG CCA ATC TGC CA q 
 
GRO  Forward GCT TGA AGG TGT TGC CCT C 
 Reverse AGG CAA GCC TCG CGA CCA T 
 Probe  f ACC CAA ACC GAA GTC ATA GCC ACA CTC q 
 
MIP-1a Forward ACC AAG TCT TCT CAG CGC CA 
 Reverse AAT CTT CCG GCT GTA GGA GA 
 Probe  f AGC TGA CAC CCC GAC TGC CTG CTG q 
 
MCP1  Forward CTG GAG CAT CCA CGT GTT G 
 Reverse TGG GAT CAT CTT GCT GGT GA 
 Probe  f AGC CAG ATG CAG TTA ACG CCC CAC T q 
 
eNOS Forward GAC AGA CTA CAC GAC ATT GAG 
 Reverse ATG GTC CAG TTG GGA GCA TC 
 Probe  f CTA CAA CCT GCC CCC ATG ACT TTG q 
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iNOS Forward GAG CCT TTA GAC CTC AAC AG 
 Reverse TGC TGG GAT TTC AGC CTC AT 
 Probe  f CCT CAG CAG CAT CCA TGC AAA GAA CG q 
 
IFN-! Forward GTG GCA TAG ATG TGG AAG AAA AGA 
 Reverse TTT CAT GTC ACC ATC CTT TTG C 
 Probe  f TC TCT TCT TGG ATA TCT GGA GGA ACT q 
 
NF-%# Forward AAG TGA TCC AGG CAG CCT TC 
 Reverse CTA TGT GCT GCC TCG TGG AG 
 Probe  f TC AGG TCC ACT GTC TGC CTC TCT CGT q 
 
MCAD  Forward GAG CAG GTT TCA AGA TCG CA 
 Reverse ACT TCG TGG CTT CGT CTA GA 
 Probe  f CTA GCC CGA CAG CGC CAG CT q 
 
#-MHC Forward AGC TCA GCC ATG CCA ACC GT 
 Reverse TGA GTG TCC TTC AGC AGA CT 
 Probe  f AGG CTC TTC ACT TGT TTC TGG GCC TCA q 
 
ANF  Forward GAG AAG ATG CCG GTA GAA GA 
 Reverse AAG CAC TGC CGT CTC TCA GA 
 Probe  f ATG CCC CCG CAG GCC CGG q 
 
Collagen I Forward AGA GCA TGA CCG ATG GAT TC 
 Reverse ATT AGG CGC AGG AAG GTC AG 
 Probe  f CTC CGA CCC CGC CGA TGT CG q 
 
Collagen III Forward          CAG TTC TAG AGG ATG GCT GT  
 Reverse           TAG TCT CAT TGC CTT GCG TG 
 Probe  f CTG TCT TGC TCC ATT CCC CAG TGT G q 
 
#-Actin Forward CTG CCT GAC GGC CAG GTC 
 Reverse CAA GAA GGA AGG CTG GAA AAG A 
 Probe  t CAC TAT TGG CAA CGA GCG GTT CCG q 
 
f, Reporter dye1 (FAM:6-carboxyfluorescein); t, Reporter dye2 (TET:Tetrachloro-6-
carboxyfluorescein); q, Quencher dye (TAMRA: 6-carboxytetramethyl1-rhodamine) 
 
Table 2.1. RT-PCR sequences. Sequences of forward, reverse primers and probes of all 
mRNA analysis. 
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Table 2.2. Relative gene expression in the liver of mice at 8hr after LPS infection 
Gene Lias+/+ Lias+/- P 
GRO 0.82±0.24 (6) 2.35±0.46 (6) 0.02 
MIP1 1.27±0.25 (6) 2.20±1.22 (6) 0.47 
MCP1 1.13±0.25 (6) 1.00±0.21 (5) 0.71 
TNF 1.28±0.29 (6) 1.92±0.22 (5) 0.12 
ICAM-1 0.90±0.11 (12) 2.72±0.96 (11) 0.06 
VCAM-1 1.00±0.16 (12) 1.73±0.26 (11) 0.03 
L-selectin 1.04±0.11 (6) 1.25±0.11 (5) 0.21 
E-selectin 1.18±0.30 (6) 1.13±0.20 (5) 0.91 
MnSOD 0.95±0.09 (12) 1.04±0.13 (11) 0.57 
iNOS 1.49±3.5 (9) 1.95±0.46 (8) 0.44 
CD14 1.06±25 (9) 1.03±0.14 (8) 0.93 
PaiI 1.06±0.15 (6) 0.75±0.19 (5) 0.22 
Table 2.2. Relative gene expression in the liver of mice at 8hr after LPS infection. Data 
are expressed as mean ±SE relative to the mean expression in the Lias+/+ liver as 1.00. The 
number of animals is in parentheses. P values between the two genotypes were calculated by 
Student’s t-test. 
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2.4 DISCUSSION 
In this study, we found that the Lias heterozygous mice are more sensitive to LPS 
induced oxidative stress and tissue damage. They develop thrombocytopenia and leucopenia 
in early phase of infection to similar degrees with wild type mice, but are significantly 
impaired in their recovery at 8 hour post infection. Higher expression of genes for GRO and 
VCAM-1 and diminished lipoic acid in the Lias heterozygous mice liver compared to wild 
type suggest that reduced ability to combat with oxidative stress caused continual recruitment 
and infiltration of neutrophils leading to an exacerbated tissue damage.  
LPS is known to induce inflammatory reactions and oxidative stress in experimental 
animals. Thrombocytopenia, leukocytosis and hyperglycemia followed by hypoglycemia are 
among the hallmarks of early endotoxinemia, and a marked increases of serum cytokines, 
such as TNF-- and IL-1, have been implicated for the cause of these symptoms. We found 
that TNF--, a pro-inflammtory cytokine, and IL-10, an anti-inflammatory cytokine were 
higher in Lias heterozygous mice than in wild type mice at 2 hour after LPS challenge. 
However, their levels at later stages and those of IL-1b and MCP-1 did not differ between the 
two genotypes, although they were markedly increased over the basal levels. NF-GH regulates 
many gene expression such as TNF-- through its binding sites in the promoter region 
(Collins et al., 1995) and the NF-GH activity in the liver increased about 4-5 fold at 8 hour 
upon LPS challenge. Nevertheless, since almost the same amount of NF-GH was activated in 
both groups, NF-GH activation may not be the major cause of the enhanced susceptibility to 
the LPS induced tissue damage of the mice with heterozygous deficiency of Lias. Similarly, 
although some evidence suggests that continual production of NO derived from up-regulation 
of NO synthase after LPS challenge may cause hepatocellular damage, either directly or 
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indirectly by forming reactive nitrogen intermediates (Li et al., 1999), we observed no 
significant differences in the NO levels in both plasma and liver between the two genotypes. 
Likewise, upregulation of iNOS gene expression induced by LPS were same in both 
genotypes. These findings differ from the effects of exogenously administered LA observed 
by other investigators. For example, Suntres reported that intraperitoneal pretreatment with 
LA significantly alleviated LPS induced tissue injuries by decreasing LPS induced TNF--
and NO concentration in plasma and lipid peroxidation in liver (Suntres, 2003). Similarly, it 
has been reported that LA inhibits the activation of NF-GH in human T cells exposed TNF--
(Roy et al., 1998) and in cultured aortic endothelial cells challenged with advanced glycation 
end products (Bierhaus et al., 1997). 
Our results showed that the neutrophil, lymphocyte and monocyte counts 
continuously drop during the first 4 hours of infection, but started to recover after 4 hours in 
wild type mice. The initial drop could be explained by destruction of peripheral blood cells, 
shift of the cells from circulating pool to the marginated pool and/or hemorrhage and 
sequestration within the tissue. The subsequent rise of blood leukocyte counts in these mice 
may be explained by cellular release from the marrow reservoir, or a reversal of the shift 
from a marginated pool to a circulating pool. Reduced Lias expression in the Lias 
heterozygous mice has almost no effect on the initial drop, even though both pro-
inflammatory TNF-- and anti-inflammatory IL-10 levels in their plasma are higher than in 
wild type mice during the early phase. However, the Lias heterozygous mice are severely 
impaired in the recovery phase. Thus, the WBC counts in these mice at 8 and 16 hours after 
infection remained low, and inflammatory cell infiltration (Leukocyte extravagation) in the 
liver and lung were more pronounced than in wild type tissue judged by the tissue MPO 
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activities and histological assessments. These were accompanied by a significant increase of 
oxidative stress biomarkers in these tissues at 8 hour after LPS administration. Increased 
expression of the gene for GRO in the liver suggests that enhanced endothelial activation and 
recruitment of neutrophils. 
The impairment in the process of leukocytes from margination back to circulation in 
the Lias heterozygous mice suggests that lipoic acid affects proteins involved in the 
leukocytes trafficking. Reactive oxygen species and other inflammatory mediators including 
cytokines activate endothelium and up-regulate the density of ICAM-1 and platelet-
endothelial cell adhesion moleculae-1 (PECAM-1) and induce exposure of P- and E-selectin 
on endothelium (Springer, 1990). Thus, we found that gene expression of VCAM-1 was 
significantly higher in the Lias heterozygous mice livers than the wild type. The expression 
of genes for ICAM showed a similar trend. In contrast, gene expression of E- or L-selectin 
was not different. Although the levels of active proteins were not measured, these results 
suggest than endogenous LA production may affect adhesiveness of endothelial cells for 
neutrophils/monocytes. This is consistent with the findings by Zhang and Frei who showed 
that exogenous LA can inhibit TNF-- induced expression of ICAM-1 and VCAM-1 at the 
mRNA level in cultured human aortic endothelial cells (Zhang and Frei, 2001) and by 
Chaudhary et al. who demonstrated the ability of lipoic acid to inhibit up-regulation of 
ICAM-1 and VCAM-1 in endothelial cells on central nervous system in mice (Chaudhary et 
al., 2006) although the detailed anti-inflammatory mechanisms of lipoic acid remain elusive. 
Thrombocytopenia commonly takes place in septic shock due to peripheral 
abnormalities associated with platelet loss or increased destruction of margination of 
activated platelets into the peripheral circulation (Stephan et al., 1999; Vincent et al., 2002). 
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LPS has been shown to increase platelet aggregation in animal model (Itoh et al., 1996; Sheu 
et al., 1999). Noticeably, neutrophil infiltration in lung of LPS treated Lias heterozygous 
mice is consistent with a report by Strange et al. that platelets attenuate oxidant-induced 
permeability in endothelial cells in glutathione-dependent mechanism (Strange et al., 1996). 
This mechanism may be also account why both platelets and WBC shared the similar 
recovery curve at 4 hour after LPS injection in wild type mice. Recently, Andonegui et al.
reported that platelets express functional levels of TLR4 ad that the presence of TLR4 on 
platelets is essential for the LPS induced thrombocytopenia (Andonegui et al., 2005). The 
authors also demonstrated that LPS induced platelet sequestration is entirely dependent upon 
neutrophil accumulation into the lung. 
Activated leukocytes and macrophages trigger a large amount of ROS production 
during sepsis. Glucose uptake of these cells increases through membrane translocation of 
Glut1 and its transcriptional up-regulation. The energy in these mitochondria-poor cells is 
then provided by the hexose-monophosphate shunt with pyruvate and lactate as end products. 
Alteration of glucose metabolism in cells, such as hepatocytes, also takes place concurrently 
with increased expression of genes for glycolytic enzymes and reduction of key enzymes in 
TCA cycle. Thus, pyruvate dehydrogenase (PDH) enzyme activity reduces through 
phosphorylation of the subunit E1 to an inactive form by increased PDH kinase activity. LPS 
challenge also results in transcriptional suppression of the PDH-E1 and E2 genes in various 
organs (Kim et al., 2006). Since the major source of the cellular ROS is through oxidative 
phosphorylation in mitochondria, reduction of oxidative metabolism is consistent with the 
body’s attempt to cope with an increased oxidative stress. In the current work, we found that 
that LPS markedly decreased the Lias gene expression. Since LA is a mandatory cofactor for 
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PDH and a-KDH, reduction of Lias also ensures the reduction of oxidative metabolism under 
sepsis. This metabolic change induced by LPS is the same as switch required for cellular 
adaptation to hypoxia, though whether sepsis induces hypoxic condition or not has been 
under continual debate, hypoxia-inducible factor 1a has been implicated to activation of 
genes such as glucose transporters, glycolytic enzymes, PDH kinase and vascular endothelial 
growth factor. Although further studies are necessary to elucidate the mechanism underlying 
the down regulation of the Lias gene expression in sepsis, one adverse consequence of this 
down regulation is the reduction of cellular antioxidant capacity, and our immunostaining of 
the liver sections provides the evidence for the profound reduction of tissue LA in the Lias 
heterozygous mice. This further contributes to the exacerbation of tissue damage. 
In summary, the present study shows that the Lias heterozygous mice are abnormally 
sensitive to LPS induced inflammatory tissue damage and suggests that endogenous LA as an 
antioxidant reduces pathological changes of inflammation in liver and lung possibly through 
quenching ROS. These results provide additional evidence that oxidative stress is an 
important factor in septic shock and basis that antioxidant therapy can be an alternative 
treatment for endotoxin infection. 
 
CHAPTER 3 
 
ASSESSMENT OF ISOPROTERENOL AND PHENYLEPHRINE INDUCED 
PATHOPHYSIOLOGY IN LIPOIC ACID SYNTHASE DEFICIENT MICE 
 
3.1 INTRODUCTION 
Cardiac hypertrophy is associated with other forms of cardiovascular diseases such 
as hypertension, cardiomyopathy, and heart failure, and chronic pressure and/or volume-
overload to the heart followed by prolonged adaptation period often results in cardiac 
hypertrophy (Grossman et al., 1975; Bohm et al., 1997; Frey, 2004). Although chronic 
pressure and volume overload can lead to cardiac hypertrophy, its dynamic and diverse 
etiology remains elusive. Despite its diverse mechanisms and stimuli, altered metabolism in 
which metabolic shift from fatty acid oxidation to glucose oxidation in the cardiomyocytes is 
one distinctive characteristics of this disease (Barger and Kelly, 1999; Leong et al., 2002;
Bilsen et al., 2003).  
Several investigations observed enhanced activity of sympathetic nervous system 
targets many downstream signaling pathways and regulates transcriptional activities lead to 
the progression of hypertrophy in animal models (Saadane et al., 1999, 2000; Iaccarino et al.,
1999). Adrenergic receptor (adrenoceptor) activation mediates the effects of epinephrine by 
various agonistic and antagonistic pathways and can be classified into two types, alpha and 
beta which the former produces excitatory responses of smooth muscle whereas the latter 
induce inhibitory responses of smooth muscle (Heinsimer et al., 1982; Lefkowits et al.,
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1984). Isoproterenol (ISO) is one of beta-1 adrenocepters known to produce inhibitory effect 
as beta-1 agonists on smooth muscle, but it produces excitatory effect on the cardiac muscle 
(Heinsimer et al., 1982; Lefkowits et al., 1984). Phenylephrine (PE) is one of alpha-1 
adrenocepter agonist which induce vasoconstriction and inhibition of cAMP production in 
cells. Both adrenergic receptor agonists have been used widely as stimuli to induce 
hypertrophy and other cardiovascular complications (Saadane et al., 1999, 2000; Iaccarino et 
al., 1999; Shannon et al., 2006; Shizukuda et al., 1998). 
Lipoic acid is a crucial component of pyruvate dehydrogenase (PDH) and alpha-
ketogluterate dehydrogenase (KDH) enzyme complexes in glucose oxidation pathway and 
production of ATP. Several investigations with animal models of cardiovascular diseases 
including hypertrophy and cardiac failure have suggested that the dearth of conserved energy 
due to aberrant metabolism is associated with abnormal cardiac output resulting in cardiac 
complications (Huss and Kelly, 2005; Bilsen et al., 2003; Ventura-Clapier et al., 2003;
Leong et al., 2003). Reduced enzymatic activities due to reduced lipoic acid synthase gene 
activity may results in altered metabolism in the heart and reduced cardiac energy output.  
In this study, I tested hypothesis that reduced lipoic acid synthase gene activity 
increases susceptibility to cardiovascular diseases such as hypertrophy and cardiac failure 
upon cardiac specific adrenergic agonist stimulation. Heterozygous Lias deficient mice and 
wild type littermates were stimulated with isoproterenol and phenylephrine, cardiac specific 
adrenergic agonists for two weeks, to increase heart rate and to induce hypertrophy. Our data 
demonstrate that both genotypes equally developed cardiac hypertrophy with increased 
HW/BW ratio, and enhanced fibrosis. However, reduced lipoic acid synthase activity appears 
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to be adaptive and protective against mortality associated with isoproterenol and 
phenylephrine induced cardiac hypertrophy.  
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3.2 MATERIALS AND METHODS 
 
3.2.1 Mice and Adrenergic Agonist Administration 
Experiments were conducted in the 5-6 months old F1 (C57/Bl6 and 129 SvEv) Lias 
heterozygous and wild type littermates. Both females and males were used. Isoproterenol 
bitartrate salt dehydrate and phenylephrine hydrochloride (Sigma-Aldrich, St Louis, MO) 
were dissolved in PBS and delivered by the ALZET mini-osmotic pump (30mg/kg/bw each, 
model #2002, DURECT Corporation, Cupertino, CA). Pump was surgically implanted 
dorsally through a small incision under the skin of anesthetized (1-4% oxygenated 
isoflourene) mice and continuously infused for 14 consecutive days (0.5Pl per hour). Control 
groups received PBS. 
 
3.2.2 ECHO Cardiogram 
ECHO cardiogram (Visualsonics, Vevo Model #660, Toronto, Ontario) was 
performed on conscious mice at two time points, before and after implantation. Parameters 
such as PWSP (left ventricular posterior wall thickness septal line), IVS (intra ventricular 
septum thickness), LVID (left ventricular internal dimension), LV Vol (left ventricular 
volume) at systolic and diastolic were measured and LV % FS (left ventricular percent 
fractional shortening) and LV % EF (left ventricular percent ejection fraction) were 
calculated. All measurements were performed on conscious and strained mice. 
 
3.2.3 Body Weight and Heart Weight Measurement 
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Body weight was measured before and after pump implantation. For the heart 
weight, mice were fasted approximately 3 to 4 hours and anaesthetized with an overdose of 
avertin (2.5%, I.P.). Heart was surgically removed, rinsed in PBS and blotted gently on paper 
and weighed. The heart to body weight ratio was calculated and determined accordingly. 
 
3.2.4 RNA Isolation and Gene Expression Analysis 
Heart tissue was transferred immediately after surgical removal and stored in RNA 
later solution (Ambion, Austin, TX) overnight. RNA isolation was done by the ABI 6700 
RNA automated robot, approximately 30 to 100mg of tissue was weighed and was put into 
1ml of lysis buffer (ABI, diluted with 1X PBS). Samples were then homogenized thoroughly 
for 30 seconds for two times. Cooled down for five minutes and stored overnight at 4°C. 
Roughly, 10 to 20Pl of proteinase K (10ug/Pl) was added into lysate, incubated at room 
temperature for an hour and then cooled down at ice for five minutes. Approximately, 200Pl
out of 1ml of lysate was applied to ABI 6700 RNA extraction robot. Remaining steps were 
followed by the manufactures’ protocol. Isolated RNA was analyzed for marker genes that 
are for hypertrophy. The relative levels and patterns of genes-MCAD, #-MHC, ANP, 
Collagen I, Collagen III and Lias were determined by real-time quantitative reverse 
transcription PCR (RT-PCR) with b-actin as the reference gene in each reaction (Kim et al.,
2002) and sequence of their primers and probe are summarized in the Table 2.1. 
 
3.2.5 Blood Sample Collection and Metabolite Measurements 
Mice were fasted for approximately 4-5 hours before collection. Retro-orbital 
bleeding was performed with heparinized capillaries to obtain blood from each animal. 
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Collection tubes were anti-coagulated with 3Pl of 0.5M of EDTA and whole blood was then 
centrifuged at 1,600g for 10 minutes at 4°C to separate the plasma. Plasma levels of glucose 
(WAKO, Richmond, VA), triglyceride (Stanbio, Boernl, TX), cholesterol (WAKO, 
Richmond, VA) and free fatty acid (WAKO, Richmond, VA) were determined by enzymatic 
reaction of 2Pl of plasma in 200Pl of commercially available solution followed by 
spectrophotometer quantitation. A portion of frozen heart tissue was homogenized in 1ml of 
ice-cold 50mM potassium phosphate buffer (pH 7.4) and then centrifuged at 4°C of 10,000g 
for 30 minutes. The level of oxidative stress was assessed by measuring the level of lipid 
peroxidation, TBARS (Thiobarbituric Reactive Substances) in plasma and heart tissue 
homogenates (Lapenna et al., 2001) and the level of lactate in heart tissue was measured as 
described (Gutmann et al., 1974). Protein concentrations of tissue homogenates were 
determined based on the Bradford method (Bio-Rad Laboratories, Hercules, CA) and known 
concentrations of BSA (bovine serum albumin) was used as a standard. 
 
3.2.6 Histological Analysis 
Heart was surgically excised, briefly rinsed in PBS and blotted on the paper. Heart 
was then cut in half horizontally and mid-top portion of the heart was immediately kept in 
4% buffered PFA (pH 7.4) solution, and then fixed overnight. Samples were trimmed next 
day for proper size and orientation and sent to the Histological Core Facility at University of 
North Carolina at Chapel Hill for further process. Three to five micron sectioned heart slides 
were stained with H&E (hematoxylin and eosin) and Masson’s trichrome staining. 
 
3.2.7 Statistical Analysis 
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Statistical analyses were carried out with JMP software (SAS, Cary, NC). Values 
reported here is mean ± SEM. Effect of genotype and drug treatment was analyzed by two-
factorial ANOVA followed by Tukey-Kramer test. Student’s t test was used for comparison 
between heterozygous and wild type mice group. P<0.05 was considered as a statistical 
significance. 
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3.3 Results 
 
3.3.1 Survival of the Lipoic Acid Synthase Deficient Mice after ISO+PE Stimuli 
During the 14 days infusion period, survival rate of mice in four groups (wild type 
group, treated and sham; Lias heterozygous group, treated and sham) were recorded. As seen 
in Figure, 3.1., the survival curves (percentile scale) of four groups were relatively remained 
similar by the day 7 (Lias+/- treated=92%, control=91%; Lias+/+ treated=80%, 
control=88%). Surprisingly, the survival rate of the wild type group with treatment 
dramatically decreased during day 7 to 14 whereas Lias heterozygous mice with treatment 
remained relatively higher (Lias+/- treated=70%, control=91%; Lias+/+ treated=20%, 
control=88%) which indicates that Lias heterozygous deficiency appears to be protective 
against isoproterenol and phenylephrine adrenocepter agonists stimulus compared to the wild 
type mice. The other two control groups of the both genotypes (Lias+/- control=91%; 
Lias+/+ control=88%) showed minimal loss during the experiment, and no significant 
reduction of viability was observed until the end of experiment. 
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Figure 3.1. Survival curves of four experimental groups after isoproterenol and 
phenylephrine administration. Percentile survival rate was determined before and during 
the experiment. The number of alive mice was divided by the total number of mice in each 
group (death of post surgery was also counted in calculation). Number of mice, n=15 (wild 
type treated), n=8 (wild type sham), n=13 (heterozygous treated), n=11 (heterozygous sham). 
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3.3.2 Body Weight, Heart Weight and HW/BW Ratio after ISO+PE Stimuli 
I measured the body weight of all mice before and after the treatment and heart 
weight after treatment. As seen in Table 3.1., the body weight was decreased (changes 
represented as delta) after the treatment in both genotypes (Lias +/- treated =-2.4±0.98g, 
control=0.38±0.7g; Lias +/+ treated=-2.3±1.2g, control=0.65±0.6g; genotypic effect, no 
significance; treatment effect, P<0.01) and their HW/BW ratio markedly increased after the 
treatment (Lias +/- treated=0.80±0.04, control=0.52±0.02; Lias +/+ treated=0.91±0.06, 
control=0.52±0.01; genotypic effect, no significance; treatment effect, P<0.0001). Thus, the 
14 days of stimulation of alpha-1 and beta-1 adrenocepter with isoproterenol and 
phenylephrine resulted in decreased body weight and increased HW/BW ratio of all treated 
mice. However, a genotypic effect of Lias deficiency after isoproterenol and phenylephrine 
treatment was not observed. 
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Table 3.1. 
Heart weight, body weight and their ratio 
Parameters WT(Sham) WT(Treat)  Lias+/-(Sham) Lias+/-(Treat) 
BW (g)-before 33.1±2.1 31.8±1.5  28.7±2.0 29.3±1.1 
BW (g)-after 33.5±2.5 29.9±1.3  29.6±2.4 26.9±2.6 
XBW (g) 0.65±0.6† -2.3±1.2† 0.38±0.7†† -2.4±0.98†† 
HW (g)-after 0.17±0.01‡ 0.27±0.02‡ 0.15±0.02‡‡ 0.22±0.02‡‡
HW/BW ratio 0.52±0.01* 0.91±0.06*  0.52±0.02** 0.80±0.04**  
 
†, P<0.01, Treatment effect on wild type; ††, P<0.01, Treatment effect on Lias heterozygous; 
‡, P<0.01, Treatment effect on wild type; ‡‡, P<0.05, Treatment effect on Lias heterozygous; 
*, P<0.0001, Treatment effect on wild type; **, P<0.0001, Treatment effect on Lias 
heterozygous. 
 
Table 3.1. Body weight, heart weight and their ratio before and after isoproterenol and 
phenylephrin administration. Body weight of all groups was measured before and after 
ISO+PE administration. The body weight (changes represented as delta) decreased on both 
genotypes (no genotypic effect). The heart weight increased after treatment on both 
genotypes (no genotypic effect), and relative heart and body weight ratio of both groups 
significantly increased after treatment (no genotypic effect); Wild type (sham, n=7; treat, 
n=12), Lias heterozygous (sham, n=10; treat, n=13). 
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3.3.3 ECHO Cardiogram 
I also examined the functionality of the heart by applying ECHO cardiogram before 
and after the treatment of all groups. As seen in Figure, 3.2 and 3.3, I observed increased 
thickness of the IVS (intraventricular septum) at diastolic in the treated Lias heterozygous 
group compared to Lias heterozygous control group (Lias +/- treated=0.6±0.13mm; Lias +/- 
control=-0.04±0.24mm, treatment effect, P<0.05) whereas wild type did not change upon 
treatment (Lias +/+ treated=0.45±0.22mm; Lias +/+ control=0.17±0.18mm, treatment effect, 
not significant). Also, IVS at systolic in the both groups markedly increased on both 
genotypes (Lias +/- treated=0.27±0.14mm, Lias +/- control=-0.19±0.2mm; Lias +/+ 
treated=0.44±0.12mm, Lias +/+ control=-0.01±0.16mm; treatment effect, P<0.01; genotype 
effect, not significant) upon the stimulus, but did not detect genotypic difference. I did not 
observe genotypic nor treatment effect on other parameters such as PWSP (left ventricular 
posterior wall thickness at diastolic and systolic), LVID (left ventricular internal dimension 
at diastolic and systolic), LV Vol (left ventricular volume at diastolic and systolic), LV % FS 
(left ventricular percent fractional shortening) and LV % EF (left ventricular percent ejection 
fraction) but observed trends of decreased LVID at diastolic and systolic and LV Vol at 
diastolic and systolic after stimulation for the both genotypes. The heart rate of four mice 
groups at before, after the ISO+PE stimulation and the difference (delta) are also assessed as 
seen in Table 3.2. The heart rate of all mice groups before and after agonist stimulation does 
not differ from each other. Moreover, the difference (represented as delta) of all mice groups 
was not statistically significant. 
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Figure 3.2. ECHO Cardiogram before and after isoproterenol and phenylephrine 
administration. ECHO cardiogram measurements before and after ISO and PE 
administration. Changes represented as delta values. PWSP (left ventricular posterior wall 
thickness septal line at diastolic and systolic), IVS (intra ventricular septum thickness at 
diastolic and systolic), LVID (left ventricular internal dimension at diastolic and systolic) 
were measured. After 14 days infusion, thickness of IVS at systolic and diastolic has 
increased in Lias heterozygous and wild type due to treatment, however, genotypic effect 
was not observed. Wild type (Sham, n=5; treat, n=7), Lias heterozygous (Sham, n=4; Treat, 
n=9), a unit is represented as millimeter. 
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Figure 3.3. ECHO Cardiogram before and after isoproterenol and phenylephrine 
administration. ECHO cardiogram measurements before and after ISO and PE 
administration. Changes represented as delta values. LV Vol (left ventricular volume at 
diastolic and systolic), LV % FS (left ventricular % fractional shortening), LV % EF (left 
ventricular % ejection fraction) were measured. After 14 days infusion, both genotypes show 
trends of decreased left ventricular volume with increased % fractional shortening and 
ejection fraction, however, did not reach statistical significance. Wild type (Sham, n=5; treat, 
n=7), Lias heterozygous (Sham, n=4; Treat, n=9), a unit is represented as ml in volume. 
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Table 3.2. 
Heart rate measurement before and after stimulation 
Parameters WT(Sham) WT(Treat)  Lias+/-(Sham)  Lias+/-(Treat) 
HR-before 602±31 570±33  647±18    609±30 
HR-after 723±16 658±58  666±78    730±14 
XHR  122±35 120±72  -13.8±76    128±44  
 
Table 3.2. ECHO Cardiogram – Heart rate changes before and after isoproterenol and 
phenylephrine administration. Heart rate was measured before and after ISO and PE 
administration. Unexpectedly, heart rate of all groups was increased; however, the changes 
(represented as delta) were not different from sham and treated groups except heterozygous 
sham group. 
Wild type (Sham, n=6; Treat, n=15), Lias heterozygous (Sham, n=9; Treat, n=13) for the 
heart rate measurement before treatment; wild type (Sham, n=6; Treat, n=6), Lias 
heterozygous (Sham, n=4; Treat, n=9) for the heart rate measurement after treatment 
Unit is represented as beat per minute (BPM). 
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3.3.4 Plasma Metabolites, TBARS and Lactate Levels after ISO+PE Stimuli 
Next, I determined the plasma levels of the glucose, triglyceride and cholesterol at 
the baseline and after stimulation to monitor their metabolic changes in the whole body over 
the experimental period. Table 3.3. represents overall changes (delta) in plasma glucose, 
triglyceride, cholesterol and FFA (free fatty acid) during the experiment, and I observed 
decreased levels of blood glucose in the wild type group compared to Lias heterozygous mice 
after treatment (Lias +/- treated=-13.0±15.0mg/dl, control=14.5±13.6mg/dl, no treatment 
effect; Lias +/+ treated=-33.8±3.4mg/dl, control=61.9±16.2mg/dl, treatment effect, P<0.01). 
The plasma triglyceride levels did not differ from genotypes after stimulation (Lias +/- 
treated=-18.3±10.8mg/dl, control=-22.5±7.5mg/dl, Lias +/+ treated=-3.8±1.5mg/dl, control=-
20.8±9.6mg/dl, no treatment effect, no genotype effect), and the cholesterol levels did not 
differ from genotypes before and after the treatment (Lias +/- treated=8.6±6.2mg/dl, 
control=17.8±3.3mg/dl, Lias +/+ treated=13.0±11.0mg/dl, control=27.1±4.2mg/dl, no 
treatment effect, no genotype effect). I also measured FFA (free fatty acid) after the 
adrenergic agonist stimulation whether the chronic infusion over two weeks influence FFA 
levels in the plasma, but did not detect any genotypic nor treatment effect on all experimental 
groups (Lias +/- treated=1.22±0.05mEQ/L, control=1.28±0.06mEQ/L, Lias +/+ 
treated=1.17±0.02mEQ/L, control=1.25±0.06mEQ/L, no treatment effect, no genotype 
effect). 
Isoproterenol and phenylephrine are adrenocepter agonists that stimulate and excite 
the cardiac functions. Chronic stimulation act as chemical stress, and often results in cardiac 
toxicity (Ishizawa et al., 2006; Rajadurai et al., 2006; Diaz-Munoz et al., 2006), so we 
assessed the plasma and tissue levels of oxidative stress by measuring the lipid peroxidation 
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(TBARS) in all four experimental groups. As seen in Table, 3.3., plasma levels of TBARS 
were not detected due to low serum levels of oxidative stress in all experimental groups. 
However, I observed significantly decreased tissue levels of TBARS in the Lias 
heterozygous mice group after stimulation (Lias +/- treated=0.06±0.02nmol/mg protein, 
control=0.09±0.01nmol/mg protein, treatment effect, P<0.05; Lias +/+ 
treated=0.05±0.01nm/mg protein, control=0.06±0.01nmol/mg protein, no treatment effect). 
As expected, levels of TBARS in the Lias heterozygous control group increased compared to 
wild type control group (Lias +/- control=0.09±0.01nmol/mg protein, Lias +/+ 
control=0.06±0.01nmol/mg protein, genotype effect, P<0.05, no treatment effect). 
Lias gene is essential for energy metabolism in the mitochondria. A previous study 
showed Lias heterozygous mice have altered metabolism with increased levels of lactate in 
liver tissue may be due to the enhanced glycolytic activity (Yi et al., 2005). Several animal 
studies have indicated that altered metabolism from the fatty acid oxidation to carbohydrate 
and glucose oxidation is associated with the hypertrophy although whether this metabolic 
switch is adaptive or maladaptive is under debates (Huss and Kelly, 2005; Ventura-Clapier et 
al., 2003; Bilsen et al., 2003). In order to determine whether the enhanced glycolytic activity 
of the Lias heterozygous mice shows altered metabolism in the heart upon the ISO and PE 
stimulation, I measured the lactate levels in the heart tissue. As seen in Table 3.3., both 
genotypes show significantly decreased level of lactate in the heart tissue after the 
stimulation, however, genotypic difference was not observed (Lias +/- 
treated=0.43±0.12mmol/mg protein, control=0.68±0.02mmol/mg protein, treatment effect, 
P<0.01; Lias +/+ treated=0.31±0.07mmol/mg protein, control=0.61±0.04mmol/mg protein, 
treatment effect, P<0.05). 
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Table 3.3. 
Measurements of biomarkers after treatment in plasma and heart tissue 
Parameters  WT(Sham) WT(Treat) Lias+/-(Sham) Lias+/-(Treat) 
XGlucose(P)  61.9±19.2** -38.8±3.4** 14.5±13.6  -13.0±15.0 
XTG(P)  -20.8±9.6 -3.8±1.5 -22.5±7.5  -18.3±10.8 
XCholesterol(P)   27.1±4.2 13.0±11.0  17.8±3.3     8.6±6.2 
FFA(P)  1.25±0.06 1.17±0.02 1.28±0.06  1.22±0.05 
TBARS(P)   ND  ND   ND        ND 
TBARS(H)  0.06±0.01‡ 0.05±0.01 0.09±0.01†‡ 0.06±0.01†
Lactate(H)  0.61±0.06* 0.31±0.08* 0.68±0.07† 0.43±0.07†
Table 3.3. Measurement of metabolites in plasma and heart tissue before and after 
isoproterenol and phenylephrine administration. Plasma levels of glucose, triglyceride, 
cholesterol, free fatty acid and TBARS and tissue levels of lactate and TBARS were 
measured before and after ISO and PE administration. Significant reduction of glucose level 
in treated wild type was detected compared to Lias heterozygous mice. Level of TBARS and 
lactate in heart tissue of both genotypes lowered after ISO and PE administration. Glucose, 
triglyceride, cholesterol and FFA levels: wild type (Sham, n=8; treat, n=3), Lias 
heterozygous (Sham, n=10; Treat, n=9), unit in glucose, triglyceride and cholesterol is 
represented as mg/dl, unit in free fatty acid is represented as mEq/L. TBARS and lactate 
levels: wild type (Sham, n=6; treat, n=3), Lias heterozygous (Sham, n=4; Treat, n=4), unit in 
TBARS is represented as nmol/mg protein in tissue, and nmol/ml in plasma, unit in lactate is 
represented as mmol/mg protein; (P), plasma levels of metabolites; (H), tissue (heart) levels 
of metabolites. 
* *, P<0.01, treatment effect on wild type (Sham vs Treat); *, P<0.05, treatment effect on wild 
type (Sham vs Treat); †, P<0.05, treatment effect on Lias heterozygous (Sham vs Treat); ‡,
P<0.05 genotype effect (wild type vs Lias heterozygous); ND, not determined. 
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3.3.5 Enhanced Expression of Hypertrophic Marker Genes and Increased Fibrosis after 
ISO+PE Stimuli 
Many animal studies have shown the effects of the ISO and PE administration on 
promoting hypertrophy and congestive heart failure by stimulating various downstream 
sympathetic pathways and target genes (Saadane et al., 1999, 2000). Expression of several 
genes including MCAD, #-MHC and ANP (ANF) are known to be altered during the process 
and used as indicators of the hypertrophy (Barger and Kelly, 1999). The relative mRNA 
expression of MCAD was decreased after agonist stimulation on both genotypes (Lias +/- 
treated=55.0±10.0, control=100±10.3, Lias +/+ treated=53.0±9.5, control=100±12.4, 
treatment effect, P<0.0001, no genotypic effect) (Fig 3.4.). The expression level of #-MHC in 
the treated heterozygous group increased compared to the treated wild type mice group (Lias 
+/- treated=233±41, control=71.4±43, Lias +/+ treated=76.2±38, control=100±53, 
treatment/genotype effect was observed, P=0.05). ANP expression level of both genotypes 
tended to increase upon the isoproterenol and phenylephrine stimulation (Lias +/- 
treated=119±19.4, control=95.2±20.4, Lias +/+ treated=120.2±16.7, control=100±24.3, no 
significant treatment/genotype effect was observed), but both genotypes did not reach 
statistical significance after infusion. Relative mRNA levels of Collagen I (Lias +/- 
treated=421±155, control=116±163, Lias +/+ treated=709±139, control=100±194, no 
genotypic effect; treatment effect, P<0.01) and Collagen III (Lias +/-, treated=212±53.8, 
control=105±56.4, Lias +/+, treated=344±51.5, control=100±67.3, no genotypic effect; 
treatment effect, P<0.01), markers for fibrosis in the heart increased significantly upon the 
treatment. These data from both groups of mice implicates that ISO and PE stimulus up-
regulated Collagen I and Collagen III mRNA expression which generally results in enhanced 
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fibrosis formation. The levels of Lias expression was not changed after ISO and PE induced 
cardiac stress on both genotypes (Lias +/-, treated=51.5±18, control=49.4±9.9, Lias +/+, 
treated=86.3±8.9, control=100±11.8, genotypic effect as expected; no treatment effect). 
Next, I assessed fibrosis formation in the heart by evaluating Masson’s trichrome 
stained heart sections (arbitrary scores were measured with degree of severity scales from 0 
to 3). As seen in Figure 3.5. and 3.6., both Lias heterozygous and wild type mice groups 
showed increased fibrosis in their heart after isoproterenol and phenylephrine stimulation 
(Lias +/- treated=2.12±0.23, control=0.65±0.48, Lias +/+ treated=2.08±0.27, 
control=0.83±0.11, no significant genotype effect was observed; treatment effect, P<0.001). 
These data indicates that both genotypes responded upon isoproterenol and phenylephrine 
cardiac stimulation regardless of their sex, and 14 days of consecutive infusion induced 
cardiac hypertrophy and cardiac fibrosis in treated mice.. 
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Figure 3.4. Relative gene expression in heart after isoproterenol and phenylephrine 
administration. After 14 days of consecutive infusion of ISO and PE, both treated groups 
showed significant decrease in MCAD, increase in Collagen I and III expression (no 
genotype effect was observed; treatment effect, P<0.01). The expression levels of ANF 
tended to increase after treatment; however, it did not reach statistical significance. Treated 
Lias heterozygous group showed increased level of #-MHC expression in the heart 
(genotype/treatment effect was observed, P=0.03). As expected, Lias gene expression is 
reduced in Lias heterozygous mice compared to wild type mice, but the relative levels of 
both genotypes did not change after treatment. 
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Lias +/+ (Sham)
Lias +/- (Sham)
Lias +/+ (Treated)
Lias +/- (Treated) X 40  
Figure 3.5. Histological analysis of heart after ISO+PE administration. The heart 
sections stained with Masson’s trichrome, an indicator of fibrosis. After 14 days of 
consecutive ISO+PE administration, both treated groups developed mild to severe fibrosis in 
their hearts, whereas sham groups developed no fibrosis. However, no genotypic effect was 
observed. 
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Figure 3.6. Arbitrary scores of heart fibrosis after ISO+PE administration. Arbitrary 
scores of heart fibrosis from the fig. 3.5. Each slide was individually analyzed and arbitrary 
score of severity was given (severity scales are from 0, none, to 3, severe). Then, average 
was calculated for all groups. After 14 days of consecutive isoproterenol and phenylephrine 
administration, both treated groups developed mild to severe fibrosis in their hearts, whereas 
sham groups did not develop fibrosis. However, no genotypic difference was observed. 
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3.4 DISCUSSION 
In this study, I have observed reduced viability of wild type mice with isoproterenol 
and phenylephrine infusion over the 14 days experiment. Surprisingly, I observed a 
protective effect of Lias heterozygosity compared to wild type littermates upon stimulation. 
Unlike other isoproterenol and pheylephrine related animal experiments, I observed 
significantly enhanced mortality in the wild type (20% survival rate) and a protective effect 
of Lias heterozygous deficiency (70% survival rate) against adrenergic stress, although the 
concentration of these two drugs was smaller than the known LD50 (Green et al., 1980).
Isoproterenol and phenylephrine are adrenergic agonists. Isoproterenol is beta-
adrenergic receptor agonist which has known to produce systemic vasodialation, 
bronchodilation, and hypotension effects (Heinsimer et al., 1982; Lefkowitz et al., 1984). 
Pheylephrine is alpha-adrenergic receptor agonist which has known to induce 
vasoconstriction, bronchodilation, and hypertension effects (Heinsimer et al., 1982;
Lefkowitz et al., 1984). Several investigations have observed synergistic effects of increased 
cardiac outputs when both drugs are used together (Shannon and Chaudhry, 2006; Saadane et 
al., 1999; Priori et al., 1993), and continuous infusion by a mini-osmotic pump resulted in 
dramatic cardiac phenotypes such as hypertrophy and congestive heart failure in animals 
(Yutzey and Robbins, 2007; Shannon and Chaudhry, 2006; Leenen, 1999; Singal, 1982; 
Mann and Bristow, 2005).  
Observations from my osmotic mini pump experiments indicate that both wild type 
and Lias heterozygous mice responded to and developed hypertrophy upon isoproterenol and 
pheylephrine stimulation. Both treated groups lost total body weight and their heart weight 
dramatically increased compared to their respective control groups. Although I did not detect 
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any significant genotypic effect after stimulus in several parameters of the ECHO 
cardiogram, I observed trends of hypertrophy in all treated groups compared to control 
groups (increased ventricular wall thickness, decreased left ventricular internal dimension 
and left ventricular volume). However, overall changes (delta) of parameters such as heart 
rate, left ventricular percent ejection fraction, and percent fraction shortening were relatively 
the same regardless of the genotypes and treatment. This discordant result of the ECHO 
cardiogram may be due to difficulties encountered during the measurements of conscious, 
strained mice and a limited number of surviving mice which prevent us from reaching 
statistical significance. 
The data from the mRNA analysis of MCAD also revealed that both genotypes 
responded and developed cardiac hypertrophy. MCAD levels of treated groups were 
significantly reduced, indicating that their fatty acid oxidation metabolism was relatively 
equally interrupted upon cardiac stimulation, although I did not detect significantly increased 
expression levels of ANP (ANF) after treatment. Interestingly, I detected significant up-
regulation of the #-MHC mRNA level in Lias heterozygous treated mice (both treatment and 
genotype effect, P<0.05). Cardimyocytes contain two isoforms of myosin heavy chain, 
alpha- and beta. #-MHC is an isoform which is predominantly present in adult hearts whereas 
-MHC is present only in developing fetal hearts (Krenz et al., 2003, 2004). Transcriptional 
activities of both isoforms are often considered as sensitive markers for hypertrophy and 
heart failure (Barger and Kelly, 1999). A previous study from Krenz et al. reported that #-
MHC transgenic mice were perfectly normal with significant reduction in contractile 
functions in their heart. However, a shift from -MHC to #-MHC under the chronic 
isoproterenol stimulation was disadvantageous although the higher expression of #-MHC is 
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theoretically beneficial and adaptive in a way of preserving energy costs in the heart (Sugiura 
et al., 1998; Holubarsch et al., 1985). Since lipoic acid is an essential cofactor for enzyme 
complexes responsible for oxidative metabolism and ATP synthesis in the mitochondria, I 
hypothesized that 50% reduction of its gene activity could be detrimental to the initiation and 
progression of cardiac disease upon chronic adrenergic agonist stimulation. Instead, I 
observed a protective effect of Lias heterozygous deficiency in this experiment. Perhaps, the 
up-regulation of the #-MHC mRNA levels in the Lias heterozygous mice upon adrenergic 
stimulation implies that altered metabolism and/or reduced ATP synthesis due to the Lias 
heterozygous deficiency could be adaptive and or advantageous regarding cardiac energy 
production and consumption. In other words, a reduction of energy metabolism due to Lias 
deficiency accompanied with enhanced #-MHC expression levels due to adrenergic agonists 
stimulation by isoproterenol and phenylephrine in the heart can be adaptive and 
advantageous in this experiment. Currently, the questions remain elusive as to whether the 
altered metabolism is adaptive or maladaptive in the progression of cardiac dysfunction, and 
further assessment in regards to Lias deficiency upon variety of cardiac stimulation is 
required. 
Our analyses of metabolites in the plasma and heart tissue also indicate that treated 
wild type mice had significantly reduced plasma glucose levels when compared to treated 
heterozygous mice, although the number of analyzed wild type mice was small. Interestingly, 
I observed that the death of treated wild type mice occurred during the fasting state in the 
middle and near the end of experiments, whereas treated heterozygous mice group were 
nearly healthy under the same environmental conditions. Several studies reported that acute 
stimulation of alpha- and beta- adrenergic receptors by administering isoproterenol and 
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phenylephrine induced hyperglycemic effect resulted from glycogenolysis from the liver 
(Shannon and Chaudhry, 2006; Vardanega-Peicher et al., 2000). However, 
pathophysiological influence and effect of prolonged stimulation by isoproterenol and 
pheylephrine on the metabolism remains unknown to date because glycogenolysis upon the 
adrenergic stimulation varies with several factors such as dosage, animal models, fasting 
period and state, ages and sex (Vardanega-Peicher et al., 2000; Garcia-Sainz et al., 1992; El-
Refai et al., 1982; Bazotte et al., 1989; Studer and Borle, 1982; Katz et al., 1987). Although I 
did not investigate the levels of glycogenolysis in the liver tissue of all experimental groups, 
it is worthwhile to assess whether there is difference in regulating metabolism and/or other 
hormonal mechanisms (such as insulin and glucagons secretion) upon chronic stimulation of 
adrenergic receptors.  
I also measured the levels of lactate in the heart tissue to test the hypothesis of 
whether the altered metabolism due to the Lias heterozygous deficiency is adaptive or 
maladaptive upon the cardiac stress since previous study showed increased levels of lactate 
in the Lias heterozygous mice because of the enhanced glycolytic activity (Yi et al., 2005). 
After stimulation, lactate levels in the heart tissue of both treated groups significantly 
decreased implicating that a shift from fatty oxidation to glycolytic pathways occurred, 
although a genotypic difference was not observed. Several metabolic enzymes in 
cardiomyocytes are upregulated and down-regulated upon prolonged cardiac stress. For 
example, pyruvate dehydorgenase complex is a multi enzyme responsible for oxidative 
metabolism and it is regulated by several kinase and phosphatase isoforms. A recent study 
from Leong et al. investigated activities of PDC and its kinase/phosphates isoforms in 
hypertrophied and non-hypertrophied hearts, and whether the altered metabolism accounts 
81
for the progression of heart diseases. They speculated that other possible molecular 
mechanisms of cardiac hypertrophy due to abnormal metabolism (pyruvate transport, NADH 
shuttles, lactate dehydrogenase and amino acid metabolism) leads to cardiac hypertrophy. 
I was unable to detect the plasma levels of lipid peroxidation (TBARS) before and 
after isoproterenol and phenylephrine stimulation, probably due to the insensitivity of the 
assay. However, I detected markedly lower levels of lipid peroxidation (TBARS) upon 
stimulation in the heart tissue after treatment. In the heart tissue, the level of TBARS of the 
Lias heterozygous control group was higher than the wild type control group as expected. 
Interestingly, the TBARS levels of both groups reduced after adrenergic stimulation and our 
data differ from current concepts and experimental results from other investigations 
(Ishizawa et al., 2006; Diaz-Munoz et al., 2006; Rajadurai et al., 2006). Several studies 
implicated that excessive alpha- and beta- adrenergic administration or stimulation produce 
cardiac toxicity and results in reactive oxygen production which will lead to aberrant cardiac 
energetic (Ishizawa et al., 2006; Diaz-Munoz et al., 2006; Rajadurai et al., 2006). However, 
it is also proposed that there are powerful counter regulatory and protective mechanisms of 
cardiomyocytes to reduce toxic effects of agonist stimulation (Shannon and Chaudhry, 2006). 
Therefore, it is worthwhile to investigate whether the acute or chronic toxicity triggered 
protective mechanisms of cardiomyocytes upon cardiac stimulation in this study. 
In this experiment, I observed the adaptive and advantageous effect of Lias 
heterozygous deficiency against cardiac specific adrenocepter stimulation. During the fasting 
state, mortality appeared to be enhanced in the treated wild type mice followed by 
hypoglycemia, whereas treated Lias heterozygous mice appeared to be normal and healthy. 
Consequently, adrenergic agonist stimulation induced cardiac hypertrophy on both genotypes 
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with increased HW/BW ratio, decreased activity of MCAD, and increased activity of 
Collagen I and III genes accompanied with enhanced fibrosis formation in their hearts. 
The question regarding to the death of wild type during this experiment remains 
unanswered at this point. Perhaps, increased mortality of the wild type groups and protective 
effect of Lias heterozygous deficiency upon isoproterenol and phenylephrine administration 
may be an independent phenotype despite overall cardiac changes in this study. For further 
assessment of effects of the Lias deficiency upon cardiac specific stimulation, several 
approaches such as a generation of animal models of cardiac specific Lias deficiency, 
pressure overload TAC aortic banding experiment, and in vitro assays of Lias deficiency with 
isoproterenol and phenylephrine stimulation experiments can be followed, and these methods 
will help us to elucidate possible molecular mechanisms and genetic effects of Lias 
deficiency on the initiation and progression of cardiac abnormalities. 
 
CHAPTER 4 
 
SUMMARY 
In this study, I examined the effects of the lipoic acid synthase heterozygous 
deficiency in regards to initiation and progression of complex human diseases upon 
exogenous oxidative stress such as lipopolysaccharide, isoproterenol and phenylephrine.  
I observed increased sensitivity of the Lias heterozygous deficiency upon LPS 
induced inflammatory response. In contrast, I observed protective and advantageous effect of 
Lias heterozygous deficiency upon isoproterenol and phenylephrine although both 
heterozygous and wild type littermates developed hypertrophy after stimulation. The 
protective effect of heterozygous deficiency upon isoproterenol and phenylephrine 
stimulation may not be associated with cardiac specific phenotype, and further investigations 
should be followed. 
Lias is an essential gene responsible for important steps in oxidative metabolism in 
mitochondria and it is also a candidate gene for metabolic and cardiovascular diseases. For 
better understanding of the initiation and progression of complex human diseases 
accompanied by variety of exogenous/endogenous insults, it is worthwhile to further explore 
the genetic and pathological impacts of Lias deficiency in mouse model. 
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